All good points, thx Kgem. About Nasdaq; certain t

All good points, thx Kgem. About Nasdaq; certain things are to be fullfilled, to be approved - all this knows Lexaria. When they applied in july, one can figure; is the company valued the same today? The good; major orders dropping in, so revenue is expected at least double according to CEO on interview. The bad; the share price - 40% decrease compared to july 20. 16-20 july the stock doubled up in value. The 4 dollar mark is to stay and trade on Nasdaq, I don`t know if one can be accepted as "try out" on a lower level? 2 dollars? Have to find out. Lexaria applied, they clearly know some thing we don`t. It could be a "warm up", get certain things approved in the application, then complete the rest and come back when the revenue and shareprice is stronger. "Expected revenue" orders not been paid for yet, do Nasdaq (as the market do), take that into account - then it would be more clear how they could apply now. Example; the 56 million CBD servings, the customers today have announced (not confirmed in contract). The 4 million servings in the last order. The 11 million dollars from Altria by the 9 of october (not confirmed). Add this up and maybe we have the Nasdaq (or partly) explanation? A strong finish the last 3 months, will get the markets attention (as we start to notice) and a couple of major announcement can double or triple the value on one trading day. Time will tell.

Robert